Kanrenol (Potassium Canrenoate)

Potassium canrenoate blocks aldosterone receptors in the distal tubules of the kidney. This inhibition prevents sodium reabsorption and potassium loss, leading to increased urinary sodium and water excretion. The resulting reduction in extracellular fluid volume lowers blood pressure and alleviates edema.

The appropriate dose of Kanrenol is determined by the prescribing clinician based on the individual patient's condition, renal function, and response to therapy. Dosage may be adjusted during treatment, and patients should follow the specific instructions provided by their healthcare professional.

Safety data for potassium canrenoate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their physician.

To request Kanrenol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Kanrenol (potassium canrenoate) and spironolactone belong to the same class of aldosterone antagonists. Both promote potassium‑sparing diuresis, but potassium canrenoate is administered intravenously in some regions and may have a slightly different metabolic profile. Clinical choice depends on patient tolerance, renal function, and physician preference.

Kanrenol should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid storing it in bathrooms or near heat sources.

Kanrenol is supplied as an oral formulation and is taken by mouth with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water; crushing or chewing is not recommended unless specifically instructed.

The most serious risks include severe hyperkalemia, which can cause life‑threatening cardiac arrhythmias, acute renal failure, and rare cases of angioedema or hepatic dysfunction. Patients should be monitored regularly for electrolyte disturbances and renal function, and any signs of muscle weakness, palpitations, or swelling should prompt immediate medical evaluation.

Kanrenol is contraindicated in patients with known hypersensitivity to potassium canrenoate, severe renal impairment, hyperkalemia, or significant hepatic dysfunction. Caution is also advised for individuals taking other potassium‑sparing agents, ACE inhibitors, ARBs, or potassium supplements. Clinicians should evaluate each patient’s medical history before prescribing.